Inquiry Basket
Loading ......
Venezuela Equine Encephalitis Viru is a mosquito borne pathogen of the alpha virus genus. It was first isolated from a horse herd in Venezuela in 1938 and can cause zoonotic diseases, mainly infecting equines and humans. The virus particles are spherical in shape, with a diameter of about 70 nanometers. The outer layer is wrapped in a lipid membrane, and the core contains a nucleic acid capsid. Antigens are divided into 6 subtypes, among which IA, IB, and IC subtypes have strong pathogenicity and are prone to causing large-scale animal epidemics.
Figure 1. Venezuela Equine Encephalitis Viru.
Venezuelan equine encephalitis virus (VEEV) — a Togaviridae Alphavirus with core targets including E1 glycoprotein, E2 glycoprotein, and capsid (C) protein — causes Venezuelan equine encephalitis/encephalomyelitis (VEE). VEE affects all equines (horses, donkeys, zebras); post-infection, equines may die suddenly or develop progressive central nervous system disorders, mediated by E2-C protein interaction and nsP3 (non-structural protein 3)-host cell binding. Humans are also susceptible: infected healthy adults show flu-like symptoms (fever, headache), while immunocompromised, elderly, or young individuals may suffer severe illness or death, linked to E1-driven viral fusion with host cell membranes.
The virus that causes VEE is mainly caused by mosquitoes biting an infected animal and then transmitting the bite and feed to another animal or person. The speed of disease transmission depends on the subtype and density of the VEE virus in the mosquito population. Localized VEE subtype refers to the disease being localized to certain regions. These serotypes usually do not spread to other sites. Local subtypes are associated with mosquito transmission cycles in rodents. These forms of the virus may cause symptoms in humans, but generally do not affect the health of horses.
Figure 2. Venezuelan equine encephalitis (VEE).
The virus is transmitted through mosquito bites, with equines as the main host and rodents playing a key role in local transmission. Human infections often present as flu like symptoms, with a few severe cases leading to encephalitis or even death. The transmission of animal epidemics is affected by mosquito population density and virus subtypes. Local subtypes are limited to specific areas, while epidemic subtypes can rapidly spread in herds of horses. In 1995, a serious epidemic broke out in Venezuela and Colombia, infecting over 10000 people and resulting in hundreds of horse deaths. Preventive measures include mosquito eradication, horse immunization, and vaccination with TC83 attenuated vaccine.
The serological test flight will execute the virus here and display six different subtypes (classified as I appearing against VI). These are teaching names, including Mucambo, Tonate, and Pixuna subtypes. There are seven different deformations in subtype I, and three of these deformations, A, B, and C, are the tension of animal epidemics.
The incubation period is 2-5 days. Most of the symptoms are flu like, including chills, fever, headache, muscle pain (obvious in the lower back and legs), nausea, vomiting, etc. There may be signs such as tachycardia, conjunctivitis, and non exudative pharyngitis. The above symptoms disappear in about 4-6 days, and only a few patients have typical manifestations of encephalitis such as drowsiness, coma, convulsions, spastic paralysis, and central respiratory failure. Mild increase in peripheral white blood cells. The cerebrospinal fluid of patients with encephalitis presents characteristics of viral encephalitis.
Diagnosis relies on virus isolation and serological testing.
Venezuelan equine encephalitis virus belongs to the group A virus of arboviruses, with antigens divided into six subtypes. The main pathogenic types causing outbreaks in humans and horses are subtypes IA, IB, and IC, while subtype II causes sporadic outbreaks in humans and mammals. After being bitten by infected arthropods, the virus replicates in local tissues and lymph nodes. The occurrence and persistence of viremia depend on the degree of virus replication in local tissues outside the nervous system, the speed of virus clearance by the monocyte macrophage system, and the appearance of specific antibodies. Different viruses invade different parts outside the nervous system. Many enveloped viruses and flaviviruses involve striated muscles and vascular endothelial cells, while Venezuelan encephalitis virus often invades myeloid and lymphoid tissues. During the viremia phase, parenchymal cells of the nervous system can be invaded, but the way in which the virus crosses the blood-brain barrier is not fully understood. It may be related to the virus passively crossing the vascular membrane and replicating within the cerebral capillaries.
There is currently no specific treatment available, mainly consisting of supportive and symptomatic treatment, as well as meticulous and thoughtful care, especially for patients with encephalitis. Currently, there is no specific treatment for VEE, and treatment mainly consists of supportive care, symptomatic management, and meticulous nursing, especially for patients with encephalitis. However, Anti-VEEV Monoclonal Antibodies have emerged as a promising targeted therapeutic strategy and have become a focus of research for potential clinical application. The key types include:
| Antibody Treatment | Details |
| Mouse Anti-VEEV Monoclonal Antibody | This antibody is derived from immunized mice and can specifically bind to the conserved antigenic epitopes of VEEV. Due to its high specificity and ease of preparation, it is widely used in basic research (such as virus tracking and pathogenic mechanism research) and the development of diagnostic reagents. |
| Human Anti-VEEV E2 A domain Monoclonal Antibody | Targeting the A domain of VEEV E2 protein (a key surface glycoprotein involved in virus invasion into host cells), this whole human antibody has low immunogenicity in the human body, reducing the risk of immune rejection. It can block the interaction between the virus and host cell receptors, thereby inhibiting the entry and replication of the virus, demonstrating great potential for treating VEE. |
| Rabbit Anti-VEEV E2 A domain Monoclonal Antibody | Similar to its human derived counterpart, it specifically recognizes the E2A domain of VEEV. It has high affinity and stability, making it suitable for applications such as virus detection (such as enzyme-linked immunosorbent assay) and preclinical treatment evaluation, supplementing the application scenarios of mouse and human derived antibodies. |
Livestock captivity, mosquito control, mosquito eradication, and horse immunization can all prevent the spread of this disease. The use of TC83 attenuated live vaccine for vaccination in adults, laboratory workers, and high-risk populations can prevent IA, IB, and IC subtype infections, and also has a certain preventive effect on ID and IE subgroups.
Loading ......
